Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage biopharmaceutical company. Inovio develops deoxyribonucleic acid (DNA)-based vaccines and immune therapies, called synthetic vaccines, in combination with electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio�s synthetic vaccines are based on the Company�s SynCon vaccine design. The Company has completed, current or planned clinical programs of its SynCon vaccines and immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, malaria and Ebola. The synthetic vaccine platform comprises the Company�s SynCon vaccine design process as well as its electroporation delivery technology. Inovio has developed a pre-clinical and clinical-stage pipeline of products.